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THE natural history of malignant melanoma in Uganda has been recently
studied in a retrospective analysis of 200 cases, and three clinical groups have been
delineated (Lewis and Kiryabwire, 1968). Group 1 (40%) consisted of patients
with a relatively long history of a localised tumour, usually on the sole ofthe foot,
with no metastases. Group 2 (48%) included patients with a primary lesion with
regional or distant metastases and a short clinical history. Group 3 (12%)
consisted of patients presenting with metastatic melanoma in whom no primary
lesion could be found. There were no distinguishing histological features among
the three groups, and the authors suggested that a difference might exist in the
host response to this tumour. Lewis (1967) also demonstrated an in vitro cyto-
toxic effect ofautologous serum against melanoma cells of Group 1 but not Group
2 patients, suggesting possible immunological differences.
The present study was undertaken to examine the immunologic status in the
patient with localised and metastatic malignant melanoma, and to determine if
defective immune mechanisms might be related to the occurrence of tumour
metastasis. To this end, a study ofcellular and humoral immunity in 19 Ugandan
patients with malignant melanoma was performed.
MATERIAL AND METHODS
All patients with a histopathological diagnosis ofmalignant melanomaadmitted
to the Lymphoma Treatment Centre or the surgical wards of the New Mulago
Hospital, Kampala, Uganda, between January 1968 and January 1969 were
studied. The patients were classified into one of the 3 clinical groups mentioned
above. All patients were studied before surgery or the administration of any
cytotoxic agents.
Cellular immunity
Dinitrochlorobenzene (DNCB)t and 5 common skin test antigens were used
to evaluate the delayed hypersensitivity response. A sensitising dose of 2000 ,tg.
ofDNCB in 0 1 ml. of acetone was applied to the medial aspect ofthe right upper
arm within a 2 cm. polyethylene ring, allowed to evaporate, and covered with an
adhesive bandage for one week (Brown et al., 1967). Fourteen days following the
sensitising dose, 50 jug. and 100 ,tg. of DNCB in 0-1 ml. acetone were similarly
* Address for reprints: John L. Ziegler, MD, Lymphoma Treatment Centre, P.O. Box 3935, Kam-
pala, Uganda.
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applied to separate sites on the right forearm. Challenge tests were read at
48 hours as positive if induration, vesicles or bullae were present.
The skin tests employed were " Brucellergen " protein nucleate (Merck, Sharp
and Dohme, West Point, Pa.); Candida albicans extract 1 : 100 (supplied as derma-
tophytin O, Holister-Stier Laboratories, Spokane, Wash.); mumps antigen (Eli
Lilly and Company, Indianapolis, Ind.); intermediate strength purified protein
derivative of tuberculin (0.0002 mg. PPD) (Parke Davis & Co., Detroit, Mich.)
and trichophyton 1: 30 (supplied as dermatophytin, Holister-Stier Laboratories,
Spokane, Wash.). Skin tests were administered as 0-1 ml. intradermal injections
in the left forearm and read at 48-72 hours as positive if greater than 5 mm. of
induration was present.
Lymphocyte transformation with phytohaemagglutinin-M (PHA) (Difco,
Detroit, Mich.) in vitro was determined by the following procedure. Twenty ml.
of heparinised blood was allowed to settle at room temperature for 1-2 hours, and
the leukocytes were counted and adjusted to a final concentration of 106/ml. with
Hyland agammaglobulinaemic newborn calfserum. One ml. ofleukocyte suspen-
sion was incubated with 2 ml. of minimal essential media containing 100 units
of streptomycin, 100 units of penicillin and 50 jig. of glutamine per ml. (Flow
Laboratories, Rockville, Md.). Cultures were prepared in duplicate with and
without 0-05 ml. of PHA, and incubated for 4 days at 370 C. Cultures were har-
vested by centrifugation at 1500 r.p.m. for 8 minutes in an International Centri-
fuge No. 269 head, fixed in a freshly prepared mixture of 1: 9 glacial acetic acid
and 9500 alcohol for 10 minutes and recentrifuged. The cells were pipetted on
slides, air dried, and stained with Giemsa's stain. For each culture 300 cell
differential counts of normal lymphocytes, lymphoblastoid lymphocytes, mitoses
and macrophages were performed and the percentage oftransformed lymphocytes
were calculated from the ratio of lymphoblastoid and mitotic cells to the total
lymphoid cells counted. Average percentages ofthe two unstimulated and PHA-
stimulated cultures were calculated separately.
Humoral immunity
Antibody response to Vi antigen* was measured following the intramuscular
administration of 100 ,tg. of antigen. Pre-immunisation and 14-day post-
immunisation serum was collected, stored at 20° C., and serum titres were deter-
mined in two-fold dilutions by a haemagglutination technique (Landy and
Lamb, 1953).
Immunoglobulin levels were measured in duplicate by the gel diffusion method
of Fahey and McKelvey (1965), using Hyland antibody-agar plates. Assays were
performed at the National Cancer Institute, Bethesda, Md., on specimens ofserum
collected and stored at -20° C. and shipped frozen from Kampala.
Controls
Twelve adult males who were hospitalised for trauma served as controls for
the Vi antibody response and immunoglobulin determinations (by the courtesy
of Mr. John Taylor, Department of Surgery, Mulago Hospital, Kampala, Uganda).
Nineteen of 20 normal Ugandan children, adolescents and young adults were
* A polysaccharide isolated from E. coli (5396/38), kindly supplied by Dr. M. E. Webster, National
Heart Institute, and prepared by Dr. J. F. Gallelei, Clinical Center Pharmacy Dept., National Institute
of Health, Bethesda, Md.
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successfully sensitised with DNCB and responded with a typical indurated or
vesicular reaction. Lymphocyte transformation with PHA was evaluated in
10 healthy African adults.
RESULTS
Table I shows the clinical features ofthe patients at the time oftesting. Eight
patients were Group 1, 9 patients were Group 2, and 2 patients were Group 3.
TABLE I.-Clinical Features ofPatients with Malignant Melanoma
Duration of
Group Patient Age Sex Primary site Metastases symptoms (months)
1 . 1 . 40 .F . RHeel . . 3
2 50 .F . L. Foot . - . 24
3 . 39 .F . R. Foot . . 4
4 . 50 .M . R. Foot . . 12
5 50 .M . L. Heel . - . 42
6 . 33 .F . R. Foot . . 12
7 . 80 .M . R. Foot . . 36
8 . 28 .M . R. Foot . - . 24
2 . 9 . 70 . F R. Heel . Inguinal, Lung, Liver . 18
10 35 . F . L. Heel . Inguinal . 12
11. 50 .F .L. Foot .Inguinal . 5
12 60 .F . RFoot . Inguinal . 12
13 . 40 .F . R. Foot . Inguinal . 24
14 . 32 . F R. Heel . Inguinal . 36
15 45 . F . R. Foot Inguinal, Liver, Lung, Brain . 10
16 . 50 .M . R. Toe . Inguinal . 24
17 . 45 . M . R. Toe Inguinal, Lung, Skin, Bone . 3
3 . 18 30 . M . . Inguinal . 6
19 26 . M . . Inguinal . 12
All patients but 2 (cases 18 and 19) had a primary lesion on the sole of the foot;
the two exceptions had groin metastases without detectable primary lesions,
although case 19 had a dark black spot on the heel which mayhave been aregressed
primary tumour. For purposes of this study Group 3 patients are considered
part of Group 2, as they manifest metastatic disease. In a number of instances
intervening circumstances (death, inadvertent discharge, or running away from
hospital) prevented the completion of assays requiring a 2 week interval (DNCB
sensitisation and Vi antibody titre).
TABLE II.-Delayed Hypersensitivity Response in Malignant Melanoma
Skin tests DNCB
No. No. No. No.
tested positive (%) tested positive (%)
Group1 . . 8 8 (100). 7 6 (86)
Groups 2 & 3 . 11 8 (73) . 6 4 (67)
Table II presents the results of skin testing and DNCB sensitisation. All
Group 1 patients and 73% of Group 2 patients had at least one positive intra-
dermal test. DNCB testing revealed 86% positive responses in Group 1 and 67%
positive responses in Group 2. The 3 Group 2 patients who had negative intra-
dermal tests were not tested for DNCB reactivity (due to death, discharge or
running away). The 2 negative DNCB reactors had positive skin tests. One
patient in Group 1 (No. 3), who had a positive DNCB developed metastases one732 ZIEGLER, LEWIS, LUYOMBYA AND KIRYABWIRE
year following surgery, and DNCB reactivity was still present. There is no differ-
ence in skin test and DNCB reactivity between Groups 1 and 2, and the delayed
hypersensitivity response in both groups appears intact.
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FIG. 1.-Lymphocyte transformation in malignant melanoma.
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FIG. 2.-Vi antibody response in malignant melanoma. (Crossbars indicate mean ± S.D.
in controls.)
Per cent lymphocyte transformation with PHA in vitro is shown in Fig. 1,
and reveals normal values in the 17 patients tested.
Antibody response to Vi antigen in 13 patients who had pre-immunisation
titres of less than 1: 8 is shown in Fig. 2. The antibody titres, expressed as
increments in tube dilution, are comparable in both clinical groups, and are within
the normal range.
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FIG. 3.-Immunoglobulin levels in malignant melanoma. (Crossbars indicate mean ± S.D.
in controls.)
Fig. 3 shows the immunoglobulin levels in Group 1 and Group 2 patients.
There is no difference in immunoglobulin levels in the two groups, and with the
exception of four patients with slightly elevated IgA or IgM levels, all the values
are within the normal range.
DISCUSSION
The clinical course of some cases of malignant melanoma is characterised by
(1) spontaneous regressions, (2) regression of primary lesions when metastases
occur, and (3) long remissions following surgical removal of tumour, which have
suggested the influence of host immunological mechanisms on the clinical behav-
iour ofthe tumour. The results ofthis study reveal no differences in immunologic
competence in patients with localised or metastatic malignant melanoma in
Uganda and no evidence ofimmunologic impairment in either cellular or humoral
responses. Thus, a generalised non-specific impairment of host immunity
cannot be implicated in the dissemination ofmalignant melanoma from a localised
site.
It is probable that tumour-specific antigenic differences may be present in the
patients with Group 1 or Group 2 melanoma. This phenomenon is suggested by
the study of Fass and co-workers (1969, unpublished data) who showed positive
delayed hypersensitivity responses to autologous tumour extracts in Group 1
but not in Group 2 melanoma patients. Other postulated mechanisms for the
loss of immunologic surveillance of tumour cells include the development of
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immunologic tolerance, immunoselection, or immunologic enhancement (Smith,
1968).
Some degree ofdepressed immunologic reactivity has been observed in patients
with other types of advanced cancer (Solowey and Rapaport, 1965; Lamb et al.,
1962; Krant et al., 1968). This phenomenon may be related to many factors,
including the type and extent of cancer, the age of the patient, the nature of the
antigenic stimulus, involvement of lymphatic tissue by tumour, chemotherapy,
radiotherapy, intercurrent or debilitating disease, and nutritional status. The
present study revealed normal immune responses in all patients with melanoma,
even though some had metastatic disease. Thus all patients are presumably
capable of initiating an anti-tumour immunologic response, and other factors
such as tumour-specific antigenicity should be investigated to explain the contain-
ment or spread ofmalignant melanoma.
SUMMARY
The natural history of malignant melanoma in Uganda suggests differences in
the immune status ofthe host in the localised (Group 1) and disseminated (Group
2) condition. Cellular and humoral immune responses were evaluated in this
study and were found to be normal in both clinical groups. Therefore, general-
ised non-specific suppression of immune mechanisms cannot explain these clinical
differences.
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